Search





Search





Markets
/
Stocks
/
nasdaq-exel
/

Exelixis Inc

EXEL

Add to Watchlist

48.160USD

+1.950+4.22%

Close 05/08, 16:00（ET）Quotes delayed by 15 min

12.11BMarket Cap

15.42P/E TTM



Exelixis Inc

48.160

+1.950+4.22%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Exelixis Inc

Currency: USD Updated: 2026-05-08

Key Insights

Exelixis Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 4 out of 384 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 47.53.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Exelixis Inc's Score

Industry at a Glance

Industry Ranking

4 / 384

Overall Ranking

39 / 4494

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Exelixis Inc Highlights

StrengthsRisks

Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 26.77% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 2.32B.

Undervalued

The company’s latest PE is 15.42, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 269.88M shares, increasing 0.42% quarter-over-quarter.

Held by Ken Fisher

Star Investor Ken Fisher holds 164.95K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.11.

Analyst Rating

Based on 20 analysts

Buy

Current Rating

47.529

Target Price

+7.61%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-08

The current financial score of Exelixis Inc is 9.18, ranking 10 out of 384 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 610.81M, representing a year-over-year increase of 9.97%, while its net profit experienced a year-over-year increase of 31.86%.

Score

Industry at a Glance

Previous score

9.18

Change



Financials

9.23

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.79

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.87

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Exelixis Inc's Company Valuation

Currency: USD Updated: 2026-05-08

The current valuation score of Exelixis Inc is 7.03, ranking 175 out of 384 in the Biotechnology & Medical Research industry. Its current P/E ratio is 15.42, which is 448.50% below the recent high of 84.56 and 8.30% above the recent low of 14.14.

Score

Industry at a Glance

Previous score

7.03

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 4/384

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-08

The current earnings forecast score of Exelixis Inc is 7.24, ranking 308 out of 384 in the Biotechnology & Medical Research industry. The average price target is 45.50, with a high of 60.00 and a low of 30.00.

Score

Industry at a Glance

Previous score

7.24

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 20 analysts

Buy

Current Rating

47.529

Target Price

+7.61%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

553

Total

Median

Average

Company name

Ratings

Analysts

Exelixis Inc

EXEL

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Beigene Ltd

ONC

Ionis Pharmaceuticals Inc

IONS

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-08

The current price momentum score of Exelixis Inc is 9.53, ranking 15 out of 384 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 50.22 and the support level at 44.80, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.58

Change

1.95

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.444

Buy

RSI(14)

61.428

Neutral

STOCH(KDJ)(9,3,3)

70.052

Buy

ATR(14)

1.756

Low Volatility

CCI(14)

130.327

Buy

Williams %R

14.022

Overbought

TRIX(12,20)

0.198

Sell

StochRSI(14)

65.990

Neutral

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

46.332

Buy

MA10

45.407

Buy

MA20

45.289

Buy

MA50

43.498

Buy

MA100

43.687

Buy

MA200

41.721

Buy

Institutional Confidence

Currency: USD Updated: 2026-05-08

The current institutional shareholding score of Exelixis Inc is 10.00, ranking 1 out of 384 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 106.24%, representing a quarter-over-quarter increase of 7.86%. The largest institutional shareholder is The Vanguard, holding a total of 25.09M shares, representing 9.98% of shares outstanding, with 4.85% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

25.71M

+2.82%

The Vanguard Group, Inc.

Star Investors

25.43M

-2.21%

Farallon Capital Management, L.L.C.

15.71M

Renaissance Technologies LLC

Star Investors

13.91M

-10.00%

AQR Capital Management, LLC

13.66M

+48.76%

State Street Investment Management (US)

10.49M

-5.61%

Fuller & Thaler Asset Management Inc.

7.96M

-4.33%

LSV Asset Management

7.75M

-0.29%

Geode Capital Management, L.L.C.

7.53M

-1.85%

Arrowstreet Capital, Limited Partnership

5.28M

+0.18%

Risk Assessment

Currency: USD Updated: 2026-05-08

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Exelixis Inc is 7.37, ranking 13 out of 384 in the Biotechnology & Medical Research industry. The company's beta value is 0.38. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.